TY - JOUR
T1 - Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization
T2 - Advantages of the heterologous DNA prime, protein boost immunization regimen
AU - Alekseeva, Ekaterina
AU - Sominskaya, Irina
AU - Skrastina, Dace
AU - Egorova, Irina
AU - Starodubova, Elizaveta
AU - Kushners, Eriks
AU - Mihailova, Marija
AU - Petrakova, Natalia
AU - Bruvere, Ruta
AU - Kozlovskaya, Tatyana
AU - Isaguliants, Maria
AU - Pumpens, Paul
N1 - Funding Information:
We thank Prof. Eva Stankevica and her group for the oligonucleotide synthesis and automatic sequencing and Ms. Natalija Gabrusheva and Ms. Irena Timofeeva for technical assistance. This work was supported by grants from the Latvian Council of Science 05.1626, ERAF VPD1/ERAF/CFLA/05/ APK/2.5.1./000021/010, EU #05-1000004-7748, the European Social Fund (ESF), the New Visby program of the Swedish Institute, CompuVac grant #LSHB-CT-2004-005246 and the Russian Foundation for Basic Research #08-04-01107-a.
PY - 2009/6/8
Y1 - 2009/6/8
N2 - Background: Hepatitis C core protein is an attractive target for HCV vaccine aimed to exterminate HCV infected cells. However, although highly immunogenic in natural infection, core appears to have low immunogenicity in experimental settings. We aimed to design an HCV vaccine prototype based on core, and devise immunization regimens that would lead to potent anti-core immune responses which circumvent the immunogenicity limitations earlier observed. Methods: Plasmids encoding core with no translation initiation signal (pCMVcore); with Kozak sequence (pCMVcoreKozak); and with HCV IRES (pCMVcoreIRES) were designed and expressed in a variety of eukaryotic cells. Polyproteins corresponding to HCV 1b amino acids (aa) 1-98 and 1-173 were expressed in E. coli. C57BL/6 mice were immunized with four 25-μg doses of pCMVcoreKozak, or pCMV (I). BALB/c mice were immunized with 100 μg of either pCMVcore, or pCMVcoreKozak, or pCMVcoreIRES, or empty pCMV (II). Lastly, BALB/c mice were immunized with 20 μg of core aa 1-98 in prime and boost, or with 100 μg of pCMVcoreKozak in prime and 20 μg of core aa 1-98 in boost (III). Antibody response, [3H]-T-incorporation, and cytokine secretion by core/core peptide-stimulated splenocytes were assessed after each immunization. Results: Plasmids differed in core-expression capacity: mouse fibroblasts transfected with pCMVcore, pCMVcoreIRES and pCMVcoreKozak expressed 0.22 ± 0.18, 0.83 ± 0.5, and 13 ± 5 ng core per cell, respectively. Single immunization with highly expressing pCMVcoreKozak induced specific IFN-γ and IL-2, and weak antibody response. Single immunization with plasmids directing low levels of core expression induced similar levels of cytokines, strong T-cell proliferation (pCMVcoreIRES), and antibodies in titer 103(pCMVcore). Boosting with pCMVcoreKozak induced low antibody response, core-specific T-cell proliferation and IFN-γ secretion that subsided after the 3rd plasmid injection. The latter also led to a decrease in specific IL-2 secretion. The best was the heterologous pCMVcoreKozak prime/ protein boost regiment that generated mixed Th1/Th2-cellular response with core-specific antibodies in titer ≥ 3 × 103. Conclusion: Thus, administration of highly expressed HCV core gene, as one large dose or repeated injections of smaller doses, may suppress core-specific immune response. Instead, the latter is induced by a heterologous DNA prime/protein boost regiment that circumvents the negative effects of intracellular core expression.
AB - Background: Hepatitis C core protein is an attractive target for HCV vaccine aimed to exterminate HCV infected cells. However, although highly immunogenic in natural infection, core appears to have low immunogenicity in experimental settings. We aimed to design an HCV vaccine prototype based on core, and devise immunization regimens that would lead to potent anti-core immune responses which circumvent the immunogenicity limitations earlier observed. Methods: Plasmids encoding core with no translation initiation signal (pCMVcore); with Kozak sequence (pCMVcoreKozak); and with HCV IRES (pCMVcoreIRES) were designed and expressed in a variety of eukaryotic cells. Polyproteins corresponding to HCV 1b amino acids (aa) 1-98 and 1-173 were expressed in E. coli. C57BL/6 mice were immunized with four 25-μg doses of pCMVcoreKozak, or pCMV (I). BALB/c mice were immunized with 100 μg of either pCMVcore, or pCMVcoreKozak, or pCMVcoreIRES, or empty pCMV (II). Lastly, BALB/c mice were immunized with 20 μg of core aa 1-98 in prime and boost, or with 100 μg of pCMVcoreKozak in prime and 20 μg of core aa 1-98 in boost (III). Antibody response, [3H]-T-incorporation, and cytokine secretion by core/core peptide-stimulated splenocytes were assessed after each immunization. Results: Plasmids differed in core-expression capacity: mouse fibroblasts transfected with pCMVcore, pCMVcoreIRES and pCMVcoreKozak expressed 0.22 ± 0.18, 0.83 ± 0.5, and 13 ± 5 ng core per cell, respectively. Single immunization with highly expressing pCMVcoreKozak induced specific IFN-γ and IL-2, and weak antibody response. Single immunization with plasmids directing low levels of core expression induced similar levels of cytokines, strong T-cell proliferation (pCMVcoreIRES), and antibodies in titer 103(pCMVcore). Boosting with pCMVcoreKozak induced low antibody response, core-specific T-cell proliferation and IFN-γ secretion that subsided after the 3rd plasmid injection. The latter also led to a decrease in specific IL-2 secretion. The best was the heterologous pCMVcoreKozak prime/ protein boost regiment that generated mixed Th1/Th2-cellular response with core-specific antibodies in titer ≥ 3 × 103. Conclusion: Thus, administration of highly expressed HCV core gene, as one large dose or repeated injections of smaller doses, may suppress core-specific immune response. Instead, the latter is induced by a heterologous DNA prime/protein boost regiment that circumvents the negative effects of intracellular core expression.
UR - http://www.scopus.com/inward/record.url?scp=67650083500&partnerID=8YFLogxK
U2 - 10.1186/1479-0556-7-7
DO - 10.1186/1479-0556-7-7
M3 - Article
AN - SCOPUS:67650083500
SN - 1479-0556
VL - 7
JO - Genetic Vaccines and Therapy
JF - Genetic Vaccines and Therapy
M1 - 7
ER -